Condition
Sickle Cell Disease, Thalassemia
Locations
France, Greece, Italy, Spain, United Kingdom, United States
Start date
10/01/2025
Identifiers
Trial ID
NN7535-7822,
NCT number NCT06609226,
Eudract number Not Available
NCT number NCT06609226,
Eudract number Not Available
Summary
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.
Trial Overview:
Treatment
DRUG: Etavopivat A
DRUG: Etavopivat B
Study type
INTERVENTIONAL
Trial duration
Jan 10 2025 - Nov 30 2029
Participants
325
Phase
III
Are you eligible?
Gender
Male and female
Age
Not Available
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.